The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing treatment outcomes of enfortumab vedotin dose reduction in metastatic bladder cancer.
 
Hal Rives
No Relationships to Disclose
 
Jordan Fredette
No Relationships to Disclose
 
Fern Anari
No Relationships to Disclose
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Daniel Geynisman
Honoraria - Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); CG Oncology (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Elizabeth Plimack
Consulting or Advisory Role - 23andMe; Abbvie; Adaptimmune; Astellas Pharma; AstraZeneca; Aura Biosciences; Bristol-Myers Squibb/Medarex; Eisai; EMD Serono; Merck; Pfizer; Seagen; Signatera; Synthekine
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Matthew Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - Adicet Bio; AVEO; Exelixis; Merck
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst)